Compare Novo Nordisk A/S (NVO) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Ishares Msci Thailand Etf — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Ishares Msci Thailand Etf trades at $71.61 (market cap $426.83M). The key difference: Novo Nordisk A/S is far larger — about 387.3× Ishares Msci Thailand Etf's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Ishares Msci Thailand Etf pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Ishares Msci Thailand Etf for 65 Days on average.
| NVO | THD | |
|---|---|---|
Market Cap | $165.31B | $426.83M |
Volume | 11,432,838 | 82,409 |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $75.06 |
52-Week Low | $35.29 | $57.86 |
Typical Hold Time | 116 Days | 65 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
THD (iShares MSCI Thailand ETF) trades at $71.61, down 0.26% with bearish technical signals from moving averages. Short interest surged 90.6% in September 2026, reaching 233,149 shares. The ETF has delivered strong 38% returns over the past year, outperforming ASEAN peers, but faces headwinds from foreign capital outflows in Asian markets. Technical indicators show oversold conditions with RSI at 28, while support levels cluster around $71.
Outlook remains cautious due to high short interest and regional capital rotation away from AI-exposed markets. The ETF's concentrated exposure to Delta Electronics creates vulnerability to profit-taking despite recent outperformance. Key risks include Thailand's economic sensitivity to global semiconductor cycles and foreign investor sentiment shifts in emerging markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
